366 related articles for article (PubMed ID: 26670663)
1. Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life.
Rowen D; Brazier J; Mukuria C; Keetharuth A; Risa Hole A; Tsuchiya A; Whyte S; Shackley P
Med Decis Making; 2016 Feb; 36(2):210-22. PubMed ID: 26670663
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Modes of Administration and Alternative Formats for Eliciting Societal Preferences for Burden of Illness.
Rowen D; Brazier J; Keetharuth A; Tsuchiya A; Mukuria C
Appl Health Econ Health Policy; 2016 Feb; 14(1):89-104. PubMed ID: 26445967
[TBL] [Abstract][Full Text] [Related]
3. Are life-extending treatments for terminal illnesses a special case? Exploring choices and societal viewpoints.
McHugh N; van Exel J; Mason H; Godwin J; Collins M; Donaldson C; Baker R
Soc Sci Med; 2018 Feb; 198():61-69. PubMed ID: 29276987
[TBL] [Abstract][Full Text] [Related]
4. Exploring the relative value of end of life QALYs: Are the comparators important?
McHugh N; Pinto-Prades JL; Baker R; Mason H; Donaldson C
Soc Sci Med; 2020 Jan; 245():112660. PubMed ID: 31765855
[TBL] [Abstract][Full Text] [Related]
5. Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment.
Skedgel C; Wailoo A; Akehurst R
Med Decis Making; 2015 Jan; 35(1):94-105. PubMed ID: 25145575
[TBL] [Abstract][Full Text] [Related]
6. Public preferences in healthcare resource allocation: A discrete choice experiment in South Korea.
Bae EY; Lim MK; Lee B; Bae G; Hong J
Health Policy; 2023 Dec; 138():104932. PubMed ID: 37924559
[TBL] [Abstract][Full Text] [Related]
7. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.
Baker R; Bateman I; Donaldson C; Jones-Lee M; Lancsar E; Loomes G; Mason H; Odejar M; Pinto Prades JL; Robinson A; Ryan M; Shackley P; Smith R; Sugden R; Wildman J;
Health Technol Assess; 2010 May; 14(27):1-162. PubMed ID: 20525460
[TBL] [Abstract][Full Text] [Related]
8. Priority to End of Life Treatments? Views of the Public in the Netherlands.
Wouters S; van Exel J; Baker R; B F Brouwer W
Value Health; 2017 Jan; 20(1):107-117. PubMed ID: 28212951
[TBL] [Abstract][Full Text] [Related]
9. QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.
Yin Y; Peng Q; Ma L; Dong Y; Sun Y; Xu S; Ding N; Liu X; Zhao M; Tang Y; Mei Z; Shao H; Yan D; Tang W
Qual Life Res; 2024 Mar; 33(3):753-765. PubMed ID: 38079024
[TBL] [Abstract][Full Text] [Related]
10. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.
Shiroiwa T; Saito S; Shimozuma K; Kodama S; Noto S; Fukuda T
Appl Health Econ Health Policy; 2016 Jun; 14(3):375-85. PubMed ID: 26940671
[TBL] [Abstract][Full Text] [Related]
11. Incremental decreases in quality-adjusted life years (QALY) associated with higher levels of depressive symptoms for U.S. Adults aged 65 years and older.
Jia H; Lubetkin EI
Health Qual Life Outcomes; 2017 Jan; 15(1):9. PubMed ID: 28077154
[TBL] [Abstract][Full Text] [Related]
12. A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data.
Wang HI; Roman E; Crouch S; Aas E; Burton C; Patmore R; Smith A
Value Health; 2018 Oct; 21(10):1176-1185. PubMed ID: 30314618
[TBL] [Abstract][Full Text] [Related]
13. Valuing the AD-5D Dementia Utility Instrument: An Estimation of a General Population Tariff.
Comans TA; Nguyen KH; Ratcliffe J; Rowen D; Mulhern B
Pharmacoeconomics; 2020 Aug; 38(8):871-881. PubMed ID: 32314315
[TBL] [Abstract][Full Text] [Related]
14. A Longer Life or a Quality Death? A Discrete Choice Experiment to Estimate the Relative Importance of Different Aspects of End-of-Life Care in the United Kingdom.
Skedgel C; Mott DJ; Elayan S; Cramb A
MDM Policy Pract; 2024; 9(1):23814683241252425. PubMed ID: 38766465
[TBL] [Abstract][Full Text] [Related]
15. Measuring the end-of-life premium in cancer using individual ex ante willingness to pay.
Olofsson S; Gerdtham UG; Hultkrantz L; Persson U
Eur J Health Econ; 2018 Jul; 19(6):807-820. PubMed ID: 28803265
[TBL] [Abstract][Full Text] [Related]
16. Valuing QALYs at the end of life.
Pinto-Prades JL; Sánchez-Martínez FI; Corbacho B; Baker R
Soc Sci Med; 2014 Jul; 113():5-14. PubMed ID: 24820408
[TBL] [Abstract][Full Text] [Related]
17. Equity Weights for Socioeconomic Position: Two Methods-Survey of Stated Preferences and Epidemiological Data.
Lal A; Mohebi M; Sweeney R; Moodie M; Peeters A; Carter R
Value Health; 2019 Feb; 22(2):247-253. PubMed ID: 30711071
[TBL] [Abstract][Full Text] [Related]
18. Valuing health at the end of life: a stated preference discrete choice experiment.
Shah KK; Tsuchiya A; Wailoo AJ
Soc Sci Med; 2015 Jan; 124():48-56. PubMed ID: 25461861
[TBL] [Abstract][Full Text] [Related]
19. Measuring utilities of severe facial disfigurement and composite tissue allotransplantation of the face in patients with severe face and neck burns from the perspectives of the general public, medical experts and patients.
Chuback J; Yarascavitch B; Yarascavitch A; Kaur MN; Martin S; Thoma A
Burns; 2015 Nov; 41(7):1524-31. PubMed ID: 26068209
[TBL] [Abstract][Full Text] [Related]
20. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
